MedTrace Logo

Study to Assess the Efficacy of Medi-Tate iTind Device

NCT02145208 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 81

Last updated 2022-04-11

No results posted yet for this study

Summary

The study will include an implantation of the iTind device and 4 follow up visits up to 12 months after the implantation.

Conditions

  • Benign Prostatic Hyperplasia (BPH)

Interventions

DEVICE

TIND System

An implant

Sponsors & Collaborators

  • Medi-Tate Ltd.

    lead INDUSTRY

Principal Investigators

  • Claude Schulman, MD · Edith cavell clinic, Belgium

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-10-31
Primary Completion
2017-12-31
Completion
2021-11-30

Countries

  • Belgium
  • Italy
  • Spain
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02145208 on ClinicalTrials.gov